Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LAM-001

Other · developed by IRulya Therapeutics

Phase 2 Most advanced trial

IRLA Developer

1 Registered trials

What is LAM-001?

LAM-001 is an agent administered by dry powder inhaler. It is studied in bronchiolitis obliterans syndrome, chronic lung allograft dysfunction and lung transplantation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Respiratory
Developer: IRulya Therapeutics Inc. (IRLA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06018766	Phase 2	Bronchiolitis Obliterans Syndrome	Recruiting	IRLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bronchiolitis Obliterans SyndromeChronic Lung Allograft DysfunctionLung Transplantation

More from IRulya Therapeutics

Apilimod Phase 2 LAM-003 Phase 1

Sources

ClinicalTrials.gov NCT06018766

Updated Oct 18, 2026. Something wrong or missing? Report it on the IRLA page.

Follow IRLA, the company behind LAM-001

See IRLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRLA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z